RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) was up 960.7% on Friday . The company traded as high as $15.91 and last traded at $15.91. Approximately 100 shares were traded during trading, a decline of 82% from the average daily volume of 550 shares. The stock had previously closed at $1.50.
RemeGen Stock Up 960.7%
The company has a fifty day moving average price of $5.28 and a 200-day moving average price of $4.42.
About RemeGen
RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.
See Also
- Five stocks we like better than RemeGen
- Utilities Stocks Explained – How and Why to Invest in Utilities
- After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught?
- The Significance of Brokerage Rankings in Stock Selection
- Alphabet: After Its Best Quarter in Decades, Is It Time to Buy?
- Financial Services Stocks Investing
- Forget Airlines—These Trucking Stocks Are Shifting Into High Gear
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
